Institutional target price of 261.97 Hong Kong dollars for QINGSONG HEALTH (02661) released the first Skill store in the medical industry, continuing to open platform valuation logic.

On March 13, QINGSONG HEALTH Group (02661) officially launched the MedClaw Skills Store, introducing the first batch of 886 standardized Skills covering eight core medical scenarios including clinical diagnosis and treatment, public health, medical imaging, medical testing, hospital management, nursing management, medical record management, and drug management. According to public information, this is the first Skill store in the medical industry. Against the background of the competition shifting from model capabilities to scenario capabilities in medical AI acceleration, the release of the MedClaw Skills Store marks QINGSONG HEALTH's further solidification of evidence-based medical capabilities into callable, reusable, and scalable standardized product units, further advancing the platform layout of medical AI. From an industry trend perspective, the competition focus of large models in medical scenarios is shifting from "will it answer" to "can it be embedded in real workflows." When doctors consult the latest guidelines, screen cutting-edge literature, compare evidence levels, form case discussions, and provide diagnostic and treatment reference opinions, what they need is not a generalized answer, but a set of professional skills designed around specific clinical tasks. The value of the MedClaw Skills Store lies in encapsulating these high-frequency, high-demand evidence-based medical capabilities into standardized Skills, shifting complex processes from temporary configuration to productized invocation, and advancing medical AI from tool attributes to platform attributes. In terms of specific product forms, the 886 Skills launched this time are organized according to real doctor workflows, forming a capability system covering eight major scenarios. In the clinical diagnosis and treatment scenario, the relevant Skills can automatically construct a PICO framework around clinical problems, call multiple databases to complete systematic literature screening, and output structured summaries; in the drug management scenario, Skills can quickly search for drug interactions, contraindications, and evidence-based drug recommendations; in the medical record management scenario, Skills can automatically generate discussion reports in line with evidence-based standards based on case data, complete with full citation chains. For medical professionals, this means transitioning from "configuring prompts and toolchains" to "selecting Skills and running them directly," further reducing the usage threshold. Seen within the context of the company's overall strategy, the Skills Store is not an isolated move but an important part of the continuous implementation of the QINGSONG HEALTH medical AI product matrix. Previously, the company launched the evidence-based medical intelligent body "MedClaw" and the MedClaw Collaboration Body, completing the upgrade from single-round Q&A to multi-intelligent body collaboration; the launch of Skills Store further complements the capability distribution and organization layer, enabling professional skills to be continuously consolidated, repeatedly invoked, and scaled. Thus, QINGSONG HEALTH is gradually forming a three-tiered medical AI product system of "evidence-based central axis - collaborative base - Skills Store," with the product matrix becoming more complete day by day. More noteworthy is that the launch of the Skills Store is not just adding a new product but is expected to strengthen the synergy efficiency between QINGSONG HEALTH's existing businesses. According to the company's publicly disclosed and market communication, QINGSONG HEALTH has accumulated AI capabilities in health management, precision marketing, intelligent underwriting, and is continuously promoting the application of AI in real health scenarios. The launch of the Skills Store further extends the AI capabilities from the backend to the front-end products, directly reaching core professional users such as doctors, which also means that the "medical" link in the company's "examination-medical-pharmaceutical-health-insurance" full-chain layout has gained a stronger technical foothold. For a health technology company, this extension from single-product to platform capability layer is often more strategically valuable than a single feature upgrade. From a capital market perspective, the continuous implementation of the AI product matrix is helping QINGSONG HEALTH open up new valuation narratives. On March 9, the company was officially included in the Hong Kong Stock Connect, meaning that Mainland investors can directly trade the company's stocks through the Shanghai-Hong Kong Stock Connect mechanism, potentially improving liquidity and investor coverage. Meanwhile, publicly available research reports show that on March 12, "Da Western" initiated coverage of the company for the first time, giving it a "buy" rating and a target price of 261.97 Hong Kong dollars. For the market, these ratings are not just a price anchor but more importantly reflect that institutions are re-evaluating the growth potential of QINGSONG HEALTH's evolution from a digital health service platform to a medical AI platform. Furthermore, in the past, market pricing for health technology companies has mostly focused on traffic capabilities, service capabilities, and the efficiency of single-point monetization; with the successive launches of the evidence-based medical intelligent body, collaboration body, and Skills Store, QINGSONG HEALTH's business model is expanding from a "health service platform" to an "AI-driven platform-type company." Especially with the inclusion in the Hong Kong Stock Connect, the first coverage by institutions, and the continuous improvement of the product matrix, the platform valuation logic of the company is becoming clearer. If subsequent third-party Skill integrations, doctor penetration, and multi-scenario collaboration further land, there may still be potential for the reassessment of its AI ecosystem value. Compared to overseas counterparts like Microsoft and Google, who have accepted AI application distribution through marketplace mechanisms, most still focus on general platform supply or enterprise service logic, with relatively limited coupling to clinical decision-making scenarios. The difference of the MedClaw Skills Store lies in its capability system being directly built on the context of evidence-based medicine work, with each Skill designed from specific clinical problems rather than generic technical interfaces. This product organization method that grows out of real medical tasks helps improve the adaptability of medical AI to scenarios and lays the foundation for opening up to third-party integrations and building a more complete ecosystem. QINGSONG HEALTH has stated that in the future, the Skills Store will continue to expand Skill coverage around clinical diagnosis and treatment, research assistance, medical education, and multi-disciplinary collaboration, and gradually open up the capability for third-party Skill integrations, promoting evidence-based medical capabilities from being "expert experience-driven" to "intelligently called-driven." Against the backdrop of the continuous implementation of the AI product matrix, the continued enhancement of business synergy, and the increasing attention from the capital market, QINGSONG HEALTH's medical AI layout is transitioning from a "technology investment period" to a "ecosystem release period."